Mangoceuticals, Inc.
MGRX
$4.91
-$0.37-7.01%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 52.24% | 245.65% | 670.89% | 8,119.10% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.24% | 245.65% | 670.89% | 8,119.10% | -- |
| Cost of Revenue | 54.52% | 256.44% | 578.99% | 7,217.07% | -- |
| Gross Profit | 50.61% | 238.07% | 740.10% | 8,706.12% | -- |
| SG&A Expenses | 11.95% | 26.29% | 84.38% | 303.96% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.88% | 37.86% | 106.07% | 286.68% | -- |
| Operating Income | -17.40% | -29.05% | -90.74% | -253.96% | -- |
| Income Before Tax | -27.45% | -40.12% | -97.83% | -356.58% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.45% | -40.12% | -97.83% | -356.58% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.43% | -40.11% | -97.83% | -356.58% | -- |
| EBIT | -17.40% | -29.05% | -90.74% | -253.96% | -- |
| EBITDA | -17.50% | -55.03% | -183.13% | -850.25% | -- |
| EPS Basic | 26.79% | 15.84% | -19.09% | -227.32% | -- |
| Normalized Basic EPS | 26.79% | 15.84% | -19.08% | -227.31% | -- |
| EPS Diluted | 26.79% | 15.84% | -19.09% | -227.32% | -- |
| Normalized Diluted EPS | 26.79% | 15.84% | -19.08% | -227.31% | -- |
| Average Basic Shares Outstanding | 75.19% | 67.30% | 69.57% | 54.64% | -- |
| Average Diluted Shares Outstanding | 75.19% | 67.30% | 69.57% | 54.64% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
